Clover Health Investments (CLOV) Investor presentation summary

Vision and strategy

• Aims to empower physicians with AI-powered technology for earlier identification, management, and treatment of chronic diseases, improving quality and accessibility of care.

• Differentiates through AI-driven physician enablement, wide PPO networks, and retaining full risk and upside, unlike traditional MA models.

• Focuses on proactive, individualized care, especially for high-risk and polychronic members, with real-time insights at the point of care.

Technology and clinical outcomes

• Clover Assistant leverages 100+ data sources and AI/ML models to generate millions of individualized insights for PCPs.

• Demonstrates 15–18% lower hospitalizations and 18–25% lower 30-day readmissions for COPD and CHF patients; CKD diagnosed 18 months earlier, diabetes treated 36 months earlier.

• Medication adherence improved by 3–5% post-visit among previously non-adherent patients.

• Achieved #1 PPO nationwide on HEDIS quality measures for two consecutive years.

Financial performance and growth

• 2Q26 GAAP net income of $28M (+$39M YoY), total revenues up 56% YoY, and MA membership up 48% YoY to ~157K.

• 2Q26 Adjusted EBITDA of $41M (+139% YoY); Adjusted SG&A as % of revenues improved by 220 bps YoY.

• Expecting positive FY26 GAAP net income, with strong medical cost performance and 3x faster growth than similar-sized MA plans.

• Full-risk cohort economics drive compounding profitability, with mature cohorts funding new membership growth.